ArticleThe American journal of gastroenterology2017
Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype.
Article in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes.Orphanet journal of rare diseases · 2023Guideline
- Fulminant Eosinophilic Myocarditis After Sequential Biologic Therapy in Ulcerative Colitis.JACC. Case reports · 2026Article
- Tissue Eosinophilia of the Colonic Mucosa as a Potential Early Predictor of Failure to Achieve Clinical Remission in Ulcerative Colitis.Medicina (Kaunas, Lithuania) · 2026Article
- Is Eosinophilic Colitis a Forerunner of Inflammatory Bowel Disease?Current gastroenterology reports · 2025Review
- Eosinophils in inflammatory bowel disease pathogenesis: an ROS-centric view.Frontiers in allergy · 2025Article
- Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical Review.Journal of clinical medicine · 2024Review
- Crohn's disease presenting with peripheral hypereosinophilia.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Article
- Inflammatory bowel diseases and eosinophilic oesophagitis: Two overlapping disorders?United European gastroenterology journal · 2024Article
- The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review.Central-European journal of immunology · 2024Review
- Hypereosinophilic Syndrome with Pulmonary Involvement in Ulcerative Colitis.JPGN reports · 2023Article
- Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis.Inflammatory bowel diseases · 2023Article
- Challenges in the diagnosis and management of IBD: a sub-Saharan African perspective.Therapeutic advances in gastroenterology · 2023Review
- Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.Genome medicine · 2022Article
- Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease.Journal of clinical medicine · 2022Article
- Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry.Inflammatory bowel diseases · 2022Article
- Case report: Eosinophilic pneumonia associated with vedolizumab therapy in a patient with ulcerative colitis.Frontiers in medicine · 2022Article
- Resolved Hypereosinophilic Syndrome and Immune Thrombocytopenic Purpura in Ulcerative Colitis Patients Post Colectomy: A Case Series and Literature Review.Journal of inflammation research · 2022Article
- The Role of Biomarkers in Surgery for Ulcerative Colitis: A Review.Journal of clinical medicine · 2021Review
- Intestinal eosinophils: multifaceted roles in tissue homeostasis and disease.Seminars in immunopathology · 2021Review
- The Clinical Characteristics and Treatment Outcomes of Concomitant Eosinophilic Esophagitis and Inflammatory Bowel Disease.Crohn's & colitis 360 · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPeripheral blood eosinophilia (PBE) in inflammatory bowel disease (IBD) is associated with ulcerative colitis (UC) and active disease. Little data exist on the long-term impact of PBE on disease course. We aimed to investigate the multi-year patterns of PBE and its impact on disease severity in a large IBD cohort.
methodsWe performed a registry analysis of a consented, prospective, natural history IBD cohort at a tertiary center from 2009 to 2014. Demographics, comorbidities, disease activity, healthcare utilization, and time to hospitalization or surgical resection of patients who displayed PBE were compared to patients without PBE.
resultsOf the 2,066 IBD patients, 19.2% developed PBE. PBE was significantly associated with UC (P<0.001), extensive colitis (P<0.001), and shorter disease duration (P=0.03). Over six years, PBE patients had more active disease (Harvey-Bradshaw Index P=0.001; ulcerative colitis activity index P<0.001), concurrent C-reactive protein elevation (P<0.001), healthcare utilization (hospitalization P<0.001, IBD surgery P<0.001), and more aggressive medical therapy (prednisone P<0.001, anti-TNF P<0.001). Patients with PBE had a significantly reduced time to hospitalization in both UC (P<0.001) and Crohn's disease (CD) (P<0.001) and reduced time to colectomy in UC (P=0.003). On multivariable modeling, PBE remained significantly associated with hospitalization and surgery in both CD and UC. New diagnosis of UC with PBE was associated with increased steroid (P=0.007) and anti-TNF (P=0.001) requirement.
conclusionThis multi-year study of a large IBD cohort suggests that peripheral blood eosinophilia represents a biomarker of a distinct IBD subgroup, with a unique inflammatory signature, and at risk for worse clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.